Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Article

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Related Videos
Matthew Nudy, MD | Credit: Penn State Health
Kelley Branch, MD, MSc | Credit: University of Washington Medicine
Sejal Shah, MD | Credit: Brigham and Women's
Related Content
Transient Elastography Deemed Reliable Method to Detect Liver Fibrosis in Patients with PsO Treated with MTX

Transient Elastography Deemed Reliable Method to Detect Liver Fibrosis in Patients with PsO Treated with MTX

April 26th 2024
Article
2024 State of the Air: Record Highs in US Particle Pollution, with Dr. John Balmes

2024 State of the Air: Record Highs in US Particle Pollution, with John Balmes, MD

April 24th 2024
Podcast
FDA Approves Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

FDA Approves Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

April 25th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations

April 19th 2024
Podcast
Pediatric Study Reveals Link Between Skin Disorder Visibility and Stigma

Pediatric Study Reveals Link Between Skin Disorder Visibility and Stigma

April 25th 2024
Article
Clinical Quiz: Lp(a) Recommendations for Patients from 2024 NLA Update on Use of Lipoprotein(a)

Clinical Quiz: Lp(a) Recommendations for Patients from 2024 NLA Update on Use of Lipoprotein(a)

April 25th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.